Silo Pharma, Inc.

Contributing Author

Recent Articles by Silo Pharma, Inc.

Oct-23	Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program SILO GlobeNewswire
Oct-08	Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth SILO GlobeNewswire
Oct-06	Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) SILO GlobeNewswire
Oct-01	Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SILO GlobeNewswire
Sep-30	Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SILO GlobeNewswire
Sep-29	Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management SILO GlobeNewswire
Sep-23	Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security SILO GlobeNewswire
Sep-16	Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy SILO GlobeNewswire
Sep-09	Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug SILO GlobeNewswire
Sep-03	Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio SILO GlobeNewswire
Aug-21	Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal SILO GlobeNewswire
Aug-19	Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway SILO GlobeNewswire
Aug-05	Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform SILO GlobeNewswire
Jul-16	Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 SILO GlobeNewswire
Jul-07	Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 SILO GlobeNewswire
Jun-25	Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market SILO GlobeNewswire
Jun-11	Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears SILO GlobeNewswire
Jun-05	Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset SILO GlobeNewswire
May-21	Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 SILO GlobeNewswire
May-16	Silo Pharma Announces Closing of $2 Million Public Offering SILO GlobeNewswire
May-15	Silo Pharma Announces Pricing of $2 Million Public Offering SILO GlobeNewswire
May-14	Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 SILO GlobeNewswire
May-14	Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories SILO GlobeNewswire

Silo Pharma, Inc.

Recent Articles by Silo Pharma, Inc.

Upgrade your FINVIZ experience